Using these two strategies, we assessed the therapeutic activity of anti-PD1 in combination with AMD3100, a small molecule antagonizing CXCR4, and anti-IL6 neutralizing antibodies, on immunotherapy-resistant triple negative 4T1 breast cancer. Here, CXCR4 is linked to breast cancer.